AI Summary
Centessa has secured court approval for Eli Lilly’s cash-and-CVR acquisition, valued at about $7.8 billion, at $38 per CNTA share plus a CVR up to $9. Closing is slated for June 24, 2026, with CNTA ADS delisting and trading halted that day. The CVR depends on milestones, creating optional upside beyond the offer price but adds payoff risk.
Sentiment Rationale
The offer establishes a near-certain price floor at $38 per CNTA, with additional CVR upside; historical takeovers of small biotechs often propel pre-close moves toward the deal price; risk remains until closing.
Trading Thesis
Trade CNTA toward the $38 cash plus CVR value, with closure expected by 6/24/2026.
Market-Moving
- Acquisition premium: $38 cash per CNTA share signals immediate upside.
- Court-sanctioned scheme; closing expected 6/24/2026; timing risk.
- CVR contingent on milestones; payout uncertain and timing variable.
- CNTA ADS delists post-close; value transfer to cashholder.
Key Facts
- Lilly offers CNTA: $38 per share cash plus up to $9 CVR.
- Total value about $7.8 billion; closing expected June 24, 2026.
- CNTA ADS last traded June 23; trading halted June 24.
- UK Takeover Code does not apply; no mandatory disclosures.
- CVR payments depend on milestones; payout uncertain and timing variable.
Companies Mentioned
- Centessa Pharmaceuticals plc (CNTA): Acquisition target; premium cash offer with CVR; closing expected 6/24/2026.
- Eli Lilly and Company (LLY): Acquirer; value $7.8B; potential strategic implications and integration risk.
M&A
Category: M&A. The article details a large, cross-border acquisition with a fixed cash component and contingent value rights, a classic M&A catalyst for CNTA.